US Patent

US9289472 — Use of HSP70 as a regulator of enzymatic activity

Method of Use · Assigned to Orphazyme AS · Expires 2029-08-11 · 3y remaining

Vulnerability score 81/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method of modulating enzymatic activity by administering or inducing Hsp70 to interact with BMP.

USPTO Abstract

The present invention concerns a method for modulating the enzymatic activity of an enzyme, wherein said enzyme interacts with BMP, said method comprising the step of administering or inducing Hsp70, or a functional fragment or variant thereof, in a form suitable for allowing interaction between BMP and Hsp70, or said functional fragment or variant thereof, and thereby modulating the enzymatic activity of an enzyme interacting with BMP.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-4021 — arimoclomol-citrate
U-4021 — arimoclomol-citrate
U-4021 — arimoclomol-citrate
U-4021 — arimoclomol-citrate

Patent Metadata

Patent number
US9289472
Jurisdiction
US
Classification
Method of Use
Expires
2029-08-11
Drug substance claim
No
Drug product claim
No
Assignee
Orphazyme AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.